Business Wire

numares Elects Kathy L. Bates as New Member of the Supervisory Board

Share

numares appoints Kathy L. Bates, MBA, as new member of the Supervisory Board with immediate effect. Ms. Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, in Rochester, Minnesota.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190910005080/en/

Kathy L. Bates, MBA, Senior Director, Laboratory Services at Mayo Clinic (Photo: Mayo Clinic)

Kathy L. Bates, MBA, Senior Director, Laboratory Services at Mayo Clinic (Photo: Mayo Clinic)

“We are delighted to welcome Kathy to the board,” says Dr. Volker Pfahlert, Chief Executive Officer of numares. “As we continue our focus on North American expansion, the depth of knowledge and relevant experience in the US healthcare will be invaluable to numares.” Ms. Bates is the first member of the Supervisory Board from the US. After starting her career in 1994, Ms. Bates completed various leading positions at Mayo Clinic and its partnership organizations. Her competence profile is supplemented by a large pool of experiences serving on the board of directors of Oncospire Genetics Inc. and on a Scientific Advisory Board for Roche Diagnostics Switzerland.

Since 2005 Kathy Bates is Senior Director, Laboratory Services and Partnership Development at Mayo Clinic, leading technology evaluations and strategic business development activities in laboratory diagnostics.

Recently, numares and Mayo Clinic Laboratories announced their collaboration to develop new diagnostic tests using the “numares model” – meaning a distinctive nuclear magnetic resonance (NMR) technology, to identify metabolite constellations for diagnostics.

At the annual general meeting Ms. Bates was elected to follow Dr. Gerd Grenner, who supported numares as member of the Supervisory Board since 2014 and left his position due to private reasons. The other Board Members, Dr. Schirmers, Dr. Ries and Dr. Kutzner were reelected. Dr. Bernhard Schirmers, Chairman of the Supervisory Board, thanked Dr. Grenner in special recognition of his many years of commitment for his achievements on behalf of the Supervisory Board.

About numares

numares, based in Regensburg, Germany, is a fast-growing innovative diagnostics company that applies machine learning to metabolic data to develop advanced analytical tests for high-throughput use in clinical diagnostics and life science research. The company’s AXINON® system employs nuclear magnetic resonance (NMR) spectroscopy to create a spectrum standardized by Magnetic Group SignalingTM (MGS®) to evaluate metabolite constellations. MGS® is a proprietary technology that enables NMR for highly standardized and rapid throughput testing. Metabolic tests are an important pillar in precision medicine to address unmet needs in cardiovascular diseases, nephrology, oncology and neurology. More information: https://www.numares.com/.

Contact information

numares
Julia Hertlein
Tel.: +49 941 280 949-14
E-Mail: julia.hertlein@numares.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Shekel Brings World’s First Micro-Market to EuroShop 202016.2.2020 11:15:00 EETPress release

Shekel Brainweigh Ltd. (ASX: SBW) and Hitachi today unveiled Capsule, the world’s first framework for a cost-effective autonomous micro-market solution based on Hitachi’s LiDAR sensors and Shekel’s Product Aware Shelves at EuroShop 2020. The first Capsule store is expected to launch in Europe in Q2 2020 and is on display at Shekel’s booth #D86 at Hall 3. “Micro-markets are the fastest growing segment of convenience shopping. We see them exploding in high traffic areas, such as workplaces, campuses, train stations and airports,” said Hideki Hayashi, Sales and Marketing Manager, Hitachi EU Ltd. “Deploying the joint Shekel-Hitachi solution enables retailers and micro-market operators to provide the 24/7 frictionless shopping experience consumers demand without sacrificing accuracy, performance or profitability.” In a recent consumer survey commissioned by Shekel, 41 percent of respondents specified that if they could return items and purchase more than one item at a time, they would be mo

Designer Outlet Croatia Builds Footfall With a New Hybrid Retail Destination and Shopper Traffic Counting Solution16.2.2020 10:00:00 EETPress release

Johnson Controls announced that Sensormatic Solutions, its leading global retail solutions portfolio, will feature its ShopperTrak visitor analytics and shopper insights in Designer Outlet Croatia. Majority-owned by Ingka Centres, the retailer has enhanced shopper traffic performance by adding an aspirational, ‘hybrid’ retail destination to the existing IKEA Store in Zagreb. The IKEA store in Zagreb opened in August 2014 and attracts 1.5m visitors annually. Boasting 38,000 sqm of retail space, it is one of the biggest IKEA-owned sites in Europe. To drive ambient footfall and encourage more store visits to the IKEA Zagreb store, Ingka Centres group (previously known as IKEA Centres) and ROS Retail Outlet Shopping, strategically opened an adjoining designer outlet centre, Designer Outlet Croatia, in June 2018. Covering 15.000 sqm of retail space, the outlet centre contains 74 stores of discounted luxury clothing brands, including Tommy Hilfiger, Calvin Klein, Guess, and adidas. It also o

Celltrion Healthcare showcases positive 1-year results for novel subcutaneous formulation of infliximab in patients with active Crohn’s disease and ulcerative colitis presented at The European Crohn's and Colitis Organisation (ECCO) annual congress14.2.2020 18:04:00 EETPress release

Celltrion Healthcare today announced new 1-year data from a randomised controlled trial to evaluate the pharmacokinetics (PK), efficacy and safety of CT-P13 subcutaneous (SC) formulation compared to the CT-P13 intravenous (IV) formulation in patients with active Crohn’s disease (CD) and ulcerative colitis (UC). Results presented at The European Crohn's and Colitis Organisation (ECCO) 2020 annual congress in Vienna, Austria demonstrated that the SC formulation of CT-P13 was comparable to the IV formulation of CT-P13 in terms of efficacy and safety throughout the 1-year treatment period.1 In the study, 131 patients were randomised at the maintenance phase (66 to the SC arm and 65 to the IV arm), of whom 105 (80.2%) patients completed the week 54 visit (55 in the SC arm and 50 in the IV arm). After loading doses of IV 5mg/kg at weeks 0 and 2, patients were randomised at week 6 to receive either SC 120 mg (<80kg) or 240 mg (≥80 kg) every 2 weeks in the SC arm, or continued on IV 5 mg/kg ev

Investigational Subcutaneous Formulation of Vedolizumab Achieves Clinical Remission at Week 52 in Patients with Moderately to Severely Active Crohn’s Disease14.2.2020 17:37:00 EETPress release

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced results from the phase 3 VISIBLE 2 clinical trial evaluating the efficacy and safety of an investigational subcutaneous (SC) formulation of the gut-selective biologic vedolizumab (Entyvio®) for use during maintenance therapy in adult patients with moderately to severely active Crohn's disease (CD). The study evaluated patients who achieved clinical response* at week 6 following two doses of open-label vedolizumab intravenous (IV) induction therapy at weeks 0 and 2.1 The results show that at week 52, significantly more patients on vedolizumab SC compared to placebo were in clinical remission (48.0% [n=132/275] vs. 34.3% [n=46/134] respectively; [p=0.008]),** meeting the study’s primary endpoint.1 These data were announced during an oral presentation at the 15th Congress of the European Crohn’s and Colitis Organisation (ECCO) in Vienna, Austria. “The VISIBLE 2 study showed that the investigational subcut

Mary Kay Participates in 2020 Generational Dermatology Palm Springs Symposium14.2.2020 16:50:00 EETPress release

Mary Kay Inc., a global beauty company and leader in skin care innovation, continued its decades-long support of the beauty and scientific communities by recently supporting the 2020 Generational Dermatology Palm Springs Symposium from Feb. 14 – 16. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200214005108/en/ Dr. Lucy Gildea, Chief Scientific Officer of Mary Kay Inc. (Photo: Mary Kay Inc.) Generational Dermatology, founded by Dr. Wendy E. Roberts, takes a multi-decade approach to the evolving aging patient, including medical, surgical and aesthetic dermatology. This symposium is targeted toward dermatologists and other core specialists at all stages of their careers. Participants join extraordinary faculty and key opinion leaders at the Omni Rancho Las Palmas, Rancho Mirage. “Our commitment to skin care science isn’t just about making new Mary Kay products,” said Dr. Lucy Gildea, Chief Scientific Officer at Mary Kay. ”Our

Seoul Global Challenge 2019-2020 Finds Success in Finding Innovative Solutions to Reduce the Fine Dust in Seoul Subway14.2.2020 16:00:00 EETPress release

The Seoul Global Challenge (hereinafter called "SGC") 2019-2020, hosted by the Seoul Metropolitan Government and organized by Seoul Business Agency (SBA) aimed at finding innovative solutions to urban problems by inviting global innovators, culminated with the awards ceremony on the 6th, according to the Seoul Metropolitan Government. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200214005140/en/ The Seoul Global Challenge 2019-2020, hosted by the Seoul Metropolitan Government and organized by SBA to find innovative solutions to urban problems by inviting global innovators, culminated with the awards ceremony. The Challenge brought 106 companies from all of the world that introduced products for competition in three categories -- tunnel, platform, and train. 3 teams were selected as winners with the most effective solution. First-place winner Corning took part in the platform category by introducing a solution using its cer

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom